Gotham Asset Management LLC Has $21.12 Million Stake in Masimo Co. (NASDAQ:MASI)

Gotham Asset Management LLC lowered its position in shares of Masimo Co. (NASDAQ:MASI) by 16.7% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 127,780 shares of the medical equipment provider’s stock after selling 25,706 shares during the quarter. Gotham Asset Management LLC’s holdings in Masimo were worth $21,122,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in the company. FMR LLC raised its position in shares of Masimo by 19.8% during the 4th quarter. FMR LLC now owns 8,097,454 shares of the medical equipment provider’s stock valued at $1,338,509,000 after acquiring an additional 1,340,836 shares during the last quarter. Capital Research Global Investors grew its stake in shares of Masimo by 80.5% during the fourth quarter. Capital Research Global Investors now owns 2,454,975 shares of the medical equipment provider’s stock worth $405,807,000 after purchasing an additional 1,094,647 shares during the period. Massachusetts Financial Services Co. MA grew its stake in shares of Masimo by 119.0% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,735,167 shares of the medical equipment provider’s stock worth $286,823,000 after purchasing an additional 943,001 shares during the period. Alliancebernstein L.P. boosted its holdings in Masimo by 1,276.9% during the fourth quarter. Alliancebernstein L.P. now owns 947,391 shares of the medical equipment provider’s stock worth $156,604,000 after buying an additional 878,587 shares during the last quarter. Finally, Corient Private Wealth LLC grew its position in shares of Masimo by 8,847.1% during the 4th quarter. Corient Private Wealth LLC now owns 347,683 shares of the medical equipment provider’s stock worth $57,472,000 after buying an additional 343,797 shares during the period. Institutional investors and hedge funds own 85.96% of the company’s stock.

Masimo Trading Up 2.3 %

NASDAQ:MASI opened at $157.18 on Friday. The company has a market cap of $8.49 billion, a P/E ratio of 108.40 and a beta of 1.23. Masimo Co. has a twelve month low of $101.61 and a twelve month high of $194.88. The business has a 50 day moving average price of $161.66 and a two-hundred day moving average price of $166.58. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.24 by $0.12. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The business had revenue of $372.00 million during the quarter, compared to the consensus estimate of $367.79 million. During the same quarter last year, the firm earned $0.77 earnings per share. The firm’s revenue for the quarter was down 24.5% compared to the same quarter last year. As a group, analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MASI. Piper Sandler reiterated an “overweight” rating and issued a $200.00 price target (down from $215.00) on shares of Masimo in a research report on Wednesday. BTIG Research set a $193.00 target price on Masimo and gave the stock a “buy” rating in a report on Wednesday. Wells Fargo & Company lowered their price target on Masimo from $205.00 to $190.00 and set an “overweight” rating for the company in a report on Wednesday. Raymond James lowered their target price on Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research note on Wednesday. Finally, Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Thursday, April 10th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, Masimo presently has an average rating of “Moderate Buy” and a consensus target price of $191.60.

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the firm’s stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now directly owns 16,581 shares in the company, valued at approximately $2,754,601.53. This trade represents a 11.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the transaction, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. This trade represents a 55.38 % decrease in their position. The disclosure for this sale can be found here. Insiders own 9.70% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.